SCHEMBL27384339

SCHEMBL27384339

Cc1cc2cc(CNC(=O)N3CCCC3)[nH]c2cc1C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.42
▸ RAB9A P51151 4/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ NPC1 O15118 3/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27384655 0.88 EIF4A3 (0.48) MAPK1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL27384854 0.88 MAPK1 (0.41) MAPK1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL27384340 0.87 EIF4A3 (0.47) MAPK1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL27384648 0.85 EIF4A3 (0.48) MAPK1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL27384336 0.83 MAPK1 (0.40) MAPK1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL27384264 0.83 MAPK1 (0.40) MAPK1RAB9ASMN1; SMN2CYP3A4CYP2C9
SCHEMBL27382487 0.82 HSD17B10 (0.46) RAB9ASMN1; SMN2CYP1A2KDM4EMEN1
SCHEMBL27382492 0.80 HSD17B10 (0.45) MAPK1RAB9ASMN1; SMN2CYP1A2KDM4E
SCHEMBL27384644 0.80 MAPK1 (0.46) MAPK1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL27384649 0.79 HTT (0.42) MAPK1RAB9ASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
Send feedback